nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydromorphone—UGT1A9—Mycophenolic acid—psoriasis	0.242	0.359	CbGbCtD
Hydromorphone—UGT1A9—Mycophenolate mofetil—psoriasis	0.135	0.2	CbGbCtD
Hydromorphone—CYP2D6—Hydroxyurea—psoriasis	0.0394	0.0583	CbGbCtD
Hydromorphone—CYP3A4—Calcitriol—psoriasis	0.0295	0.0436	CbGbCtD
Hydromorphone—CYP2C9—Cholecalciferol—psoriasis	0.0261	0.0386	CbGbCtD
Hydromorphone—CYP2D6—Cholecalciferol—psoriasis	0.0239	0.0353	CbGbCtD
Hydromorphone—CYP3A4—Methoxsalen—psoriasis	0.0229	0.0339	CbGbCtD
Hydromorphone—CYP2C9—Cyclosporine—psoriasis	0.0172	0.0254	CbGbCtD
Hydromorphone—CYP2D6—Cyclosporine—psoriasis	0.0157	0.0232	CbGbCtD
Hydromorphone—CYP3A4—Cholecalciferol—psoriasis	0.0152	0.0225	CbGbCtD
Hydromorphone—CYP3A4—Triamcinolone—psoriasis	0.0132	0.0195	CbGbCtD
Hydromorphone—CYP3A4—Mycophenolate mofetil—psoriasis	0.0132	0.0195	CbGbCtD
Hydromorphone—CYP2C9—Dexamethasone—psoriasis	0.0113	0.0167	CbGbCtD
Hydromorphone—CYP3A4—Betamethasone—psoriasis	0.0113	0.0167	CbGbCtD
Hydromorphone—CYP3A4—Prednisolone—psoriasis	0.0111	0.0165	CbGbCtD
Hydromorphone—CYP3A4—Hydrocortisone—psoriasis	0.0106	0.0156	CbGbCtD
Hydromorphone—CYP3A4—Prednisone—psoriasis	0.0105	0.0156	CbGbCtD
Hydromorphone—CYP2D6—Dexamethasone—psoriasis	0.0103	0.0153	CbGbCtD
Hydromorphone—CYP3A4—Cyclosporine—psoriasis	0.00997	0.0148	CbGbCtD
Hydromorphone—CYP3A4—Dexamethasone—psoriasis	0.00657	0.00972	CbGbCtD
Hydromorphone—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000936	0.054	CbGpPWpGaD
Hydromorphone—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000928	0.0535	CbGpPWpGaD
Hydromorphone—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000873	0.0504	CbGpPWpGaD
Hydromorphone—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00058	0.0335	CbGpPWpGaD
Hydromorphone—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000575	0.0332	CbGpPWpGaD
Hydromorphone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000379	0.0219	CbGpPWpGaD
Hydromorphone—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000368	0.0213	CbGpPWpGaD
Hydromorphone—OPRD1—G alpha (i) signalling events—HCAR2—psoriasis	0.000273	0.0157	CbGpPWpGaD
Hydromorphone—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000272	0.0157	CbGpPWpGaD
Hydromorphone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000267	0.0154	CbGpPWpGaD
Hydromorphone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000241	0.0139	CbGpPWpGaD
Hydromorphone—UGT1A9—Biological oxidations—CYP2S1—psoriasis	0.00024	0.0138	CbGpPWpGaD
Hydromorphone—OPRK1—G alpha (i) signalling events—HCAR2—psoriasis	0.000239	0.0138	CbGpPWpGaD
Hydromorphone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000239	0.0138	CbGpPWpGaD
Hydromorphone—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000238	0.0137	CbGpPWpGaD
Hydromorphone—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	0.000237	0.0137	CbGpPWpGaD
Hydromorphone—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000236	0.0136	CbGpPWpGaD
Hydromorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000217	0.0125	CbGpPWpGaD
Hydromorphone—OPRM1—G alpha (i) signalling events—HCAR2—psoriasis	0.000202	0.0117	CbGpPWpGaD
Hydromorphone—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000196	0.0113	CbGpPWpGaD
Hydromorphone—OPRM1—TCR Signaling Pathway—REL—psoriasis	0.000195	0.0113	CbGpPWpGaD
Hydromorphone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000195	0.0113	CbGpPWpGaD
Hydromorphone—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000194	0.0112	CbGpPWpGaD
Hydromorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00019	0.011	CbGpPWpGaD
Hydromorphone—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000177	0.0102	CbGpPWpGaD
Hydromorphone—OPRD1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000168	0.00969	CbGpPWpGaD
Hydromorphone—OPRM1—IL4-mediated signaling events—SOCS1—psoriasis	0.000168	0.00969	CbGpPWpGaD
Hydromorphone—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	0.000168	0.00967	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR ligand binding—HCAR2—psoriasis	0.000165	0.00953	CbGpPWpGaD
Hydromorphone—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	0.000164	0.00949	CbGpPWpGaD
Hydromorphone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000164	0.00946	CbGpPWpGaD
Hydromorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000161	0.00928	CbGpPWpGaD
Hydromorphone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000158	0.00909	CbGpPWpGaD
Hydromorphone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000155	0.00897	CbGpPWpGaD
Hydromorphone—OPRM1—IL4-mediated signaling events—IL10—psoriasis	0.000151	0.00869	CbGpPWpGaD
Hydromorphone—OPRK1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000147	0.0085	CbGpPWpGaD
Hydromorphone—OPRM1—IL4-mediated signaling events—IL4—psoriasis	0.000146	0.00845	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR ligand binding—HCAR2—psoriasis	0.000145	0.00836	CbGpPWpGaD
Hydromorphone—OPRD1—G alpha (i) signalling events—CCL20—psoriasis	0.000142	0.00818	CbGpPWpGaD
Hydromorphone—UGT1A9—NRF2 pathway—TGFA—psoriasis	0.000134	0.00771	CbGpPWpGaD
Hydromorphone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000128	0.00737	CbGpPWpGaD
Hydromorphone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000126	0.00727	CbGpPWpGaD
Hydromorphone—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000124	0.00718	CbGpPWpGaD
Hydromorphone—OPRK1—G alpha (i) signalling events—CCL20—psoriasis	0.000124	0.00717	CbGpPWpGaD
Hydromorphone—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000123	0.0071	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR ligand binding—HCAR2—psoriasis	0.000122	0.00706	CbGpPWpGaD
Hydromorphone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000115	0.00663	CbGpPWpGaD
Hydromorphone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000113	0.00652	CbGpPWpGaD
Hydromorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000113	0.0065	CbGpPWpGaD
Hydromorphone—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	0.000111	0.00638	CbGpPWpGaD
Hydromorphone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00011	0.00633	CbGpPWpGaD
Hydromorphone—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	0.000105	0.00606	CbGpPWpGaD
Hydromorphone—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000104	0.00599	CbGpPWpGaD
Hydromorphone—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000103	0.00593	CbGpPWpGaD
Hydromorphone—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000102	0.0059	CbGpPWpGaD
Hydromorphone—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000101	0.00585	CbGpPWpGaD
Hydromorphone—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000101	0.0058	CbGpPWpGaD
Hydromorphone—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.0001	0.0058	CbGpPWpGaD
Hydromorphone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	9.94e-05	0.00574	CbGpPWpGaD
Hydromorphone—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	9.93e-05	0.00573	CbGpPWpGaD
Hydromorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9.88e-05	0.0057	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	9.33e-05	0.00539	CbGpPWpGaD
Hydromorphone—Urticaria—Cyclosporine—psoriasis	8.61e-05	0.00028	CcSEcCtD
Hydromorphone—Myalgia—Dexamethasone—psoriasis	8.59e-05	0.00028	CcSEcCtD
Hydromorphone—Myalgia—Betamethasone—psoriasis	8.59e-05	0.00028	CcSEcCtD
Hydromorphone—OPRD1—GPCR ligand binding—CCL20—psoriasis	8.58e-05	0.00495	CbGpPWpGaD
Hydromorphone—Abdominal pain—Cyclosporine—psoriasis	8.57e-05	0.000279	CcSEcCtD
Hydromorphone—Body temperature increased—Cyclosporine—psoriasis	8.57e-05	0.000279	CcSEcCtD
Hydromorphone—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	8.57e-05	0.00494	CbGpPWpGaD
Hydromorphone—Anxiety—Betamethasone—psoriasis	8.56e-05	0.000279	CcSEcCtD
Hydromorphone—Anxiety—Dexamethasone—psoriasis	8.56e-05	0.000279	CcSEcCtD
Hydromorphone—Vomiting—Mycophenolic acid—psoriasis	8.52e-05	0.000277	CcSEcCtD
Hydromorphone—Discomfort—Dexamethasone—psoriasis	8.49e-05	0.000276	CcSEcCtD
Hydromorphone—Discomfort—Betamethasone—psoriasis	8.49e-05	0.000276	CcSEcCtD
Hydromorphone—Dyspepsia—Hydrocortisone—psoriasis	8.48e-05	0.000276	CcSEcCtD
Hydromorphone—OPRD1—Signaling by GPCR—HCAR2—psoriasis	8.48e-05	0.00489	CbGpPWpGaD
Hydromorphone—Rash—Mycophenolic acid—psoriasis	8.45e-05	0.000275	CcSEcCtD
Hydromorphone—Dermatitis—Mycophenolic acid—psoriasis	8.44e-05	0.000275	CcSEcCtD
Hydromorphone—Pain—Prednisolone—psoriasis	8.44e-05	0.000275	CcSEcCtD
Hydromorphone—Urticaria—Mycophenolate mofetil—psoriasis	8.4e-05	0.000274	CcSEcCtD
Hydromorphone—Headache—Mycophenolic acid—psoriasis	8.4e-05	0.000273	CcSEcCtD
Hydromorphone—Decreased appetite—Hydrocortisone—psoriasis	8.38e-05	0.000273	CcSEcCtD
Hydromorphone—Abdominal pain—Mycophenolate mofetil—psoriasis	8.36e-05	0.000272	CcSEcCtD
Hydromorphone—Body temperature increased—Mycophenolate mofetil—psoriasis	8.36e-05	0.000272	CcSEcCtD
Hydromorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.35e-05	0.00482	CbGpPWpGaD
Hydromorphone—Urinary tract disorder—Methotrexate—psoriasis	8.33e-05	0.000271	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Hydrocortisone—psoriasis	8.32e-05	0.000271	CcSEcCtD
Hydromorphone—Fatigue—Hydrocortisone—psoriasis	8.31e-05	0.00027	CcSEcCtD
Hydromorphone—Vision blurred—Prednisone—psoriasis	8.28e-05	0.00027	CcSEcCtD
Hydromorphone—Urethral disorder—Methotrexate—psoriasis	8.27e-05	0.000269	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Triamcinolone—psoriasis	8.27e-05	0.000269	CcSEcCtD
Hydromorphone—Pain—Hydrocortisone—psoriasis	8.24e-05	0.000268	CcSEcCtD
Hydromorphone—Anaphylactic shock—Dexamethasone—psoriasis	8.23e-05	0.000268	CcSEcCtD
Hydromorphone—Anaphylactic shock—Betamethasone—psoriasis	8.23e-05	0.000268	CcSEcCtD
Hydromorphone—Insomnia—Triamcinolone—psoriasis	8.21e-05	0.000267	CcSEcCtD
Hydromorphone—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	8.18e-05	0.00472	CbGpPWpGaD
Hydromorphone—Infection—Betamethasone—psoriasis	8.18e-05	0.000266	CcSEcCtD
Hydromorphone—Infection—Dexamethasone—psoriasis	8.18e-05	0.000266	CcSEcCtD
Hydromorphone—Ill-defined disorder—Prednisone—psoriasis	8.15e-05	0.000265	CcSEcCtD
Hydromorphone—Paraesthesia—Triamcinolone—psoriasis	8.15e-05	0.000265	CcSEcCtD
Hydromorphone—Feeling abnormal—Prednisolone—psoriasis	8.13e-05	0.000265	CcSEcCtD
Hydromorphone—Visual impairment—Methotrexate—psoriasis	8.13e-05	0.000265	CcSEcCtD
Hydromorphone—Shock—Dexamethasone—psoriasis	8.1e-05	0.000264	CcSEcCtD
Hydromorphone—Shock—Betamethasone—psoriasis	8.1e-05	0.000264	CcSEcCtD
Hydromorphone—Dyspnoea—Triamcinolone—psoriasis	8.09e-05	0.000263	CcSEcCtD
Hydromorphone—Nervous system disorder—Dexamethasone—psoriasis	8.07e-05	0.000263	CcSEcCtD
Hydromorphone—Nervous system disorder—Betamethasone—psoriasis	8.07e-05	0.000263	CcSEcCtD
Hydromorphone—Agitation—Prednisone—psoriasis	8.07e-05	0.000263	CcSEcCtD
Hydromorphone—Tachycardia—Betamethasone—psoriasis	8.04e-05	0.000262	CcSEcCtD
Hydromorphone—Tachycardia—Dexamethasone—psoriasis	8.04e-05	0.000262	CcSEcCtD
Hydromorphone—Angioedema—Prednisone—psoriasis	8.03e-05	0.000261	CcSEcCtD
Hydromorphone—Hypersensitivity—Cyclosporine—psoriasis	7.99e-05	0.00026	CcSEcCtD
Hydromorphone—Dyspepsia—Triamcinolone—psoriasis	7.99e-05	0.00026	CcSEcCtD
Hydromorphone—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	7.98e-05	0.0046	CbGpPWpGaD
Hydromorphone—Nausea—Mycophenolic acid—psoriasis	7.96e-05	0.000259	CcSEcCtD
Hydromorphone—Hyperhidrosis—Betamethasone—psoriasis	7.96e-05	0.000259	CcSEcCtD
Hydromorphone—Hyperhidrosis—Dexamethasone—psoriasis	7.96e-05	0.000259	CcSEcCtD
Hydromorphone—Feeling abnormal—Hydrocortisone—psoriasis	7.94e-05	0.000258	CcSEcCtD
Hydromorphone—Malaise—Prednisone—psoriasis	7.92e-05	0.000258	CcSEcCtD
Hydromorphone—Vertigo—Prednisone—psoriasis	7.89e-05	0.000257	CcSEcCtD
Hydromorphone—Eye disorder—Methotrexate—psoriasis	7.88e-05	0.000257	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Hydrocortisone—psoriasis	7.88e-05	0.000257	CcSEcCtD
Hydromorphone—Syncope—Prednisone—psoriasis	7.88e-05	0.000256	CcSEcCtD
Hydromorphone—Tinnitus—Methotrexate—psoriasis	7.86e-05	0.000256	CcSEcCtD
Hydromorphone—Anorexia—Dexamethasone—psoriasis	7.85e-05	0.000255	CcSEcCtD
Hydromorphone—Anorexia—Betamethasone—psoriasis	7.85e-05	0.000255	CcSEcCtD
Hydromorphone—Urticaria—Prednisolone—psoriasis	7.84e-05	0.000255	CcSEcCtD
Hydromorphone—Cardiac disorder—Methotrexate—psoriasis	7.83e-05	0.000255	CcSEcCtD
Hydromorphone—Fatigue—Triamcinolone—psoriasis	7.82e-05	0.000255	CcSEcCtD
Hydromorphone—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.79e-05	0.000254	CcSEcCtD
Hydromorphone—Asthenia—Cyclosporine—psoriasis	7.78e-05	0.000253	CcSEcCtD
Hydromorphone—Pain—Triamcinolone—psoriasis	7.76e-05	0.000253	CcSEcCtD
Hydromorphone—Loss of consciousness—Prednisone—psoriasis	7.72e-05	0.000251	CcSEcCtD
Hydromorphone—Hypotension—Dexamethasone—psoriasis	7.69e-05	0.00025	CcSEcCtD
Hydromorphone—Hypotension—Betamethasone—psoriasis	7.69e-05	0.00025	CcSEcCtD
Hydromorphone—Pruritus—Cyclosporine—psoriasis	7.67e-05	0.00025	CcSEcCtD
Hydromorphone—Urticaria—Hydrocortisone—psoriasis	7.66e-05	0.000249	CcSEcCtD
Hydromorphone—Angiopathy—Methotrexate—psoriasis	7.65e-05	0.000249	CcSEcCtD
Hydromorphone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.65e-05	0.00441	CbGpPWpGaD
Hydromorphone—Immune system disorder—Methotrexate—psoriasis	7.62e-05	0.000248	CcSEcCtD
Hydromorphone—Abdominal pain—Hydrocortisone—psoriasis	7.62e-05	0.000248	CcSEcCtD
Hydromorphone—Body temperature increased—Hydrocortisone—psoriasis	7.62e-05	0.000248	CcSEcCtD
Hydromorphone—Convulsion—Prednisone—psoriasis	7.61e-05	0.000248	CcSEcCtD
Hydromorphone—Mediastinal disorder—Methotrexate—psoriasis	7.6e-05	0.000247	CcSEcCtD
Hydromorphone—Asthenia—Mycophenolate mofetil—psoriasis	7.59e-05	0.000247	CcSEcCtD
Hydromorphone—Hypertension—Prednisone—psoriasis	7.58e-05	0.000247	CcSEcCtD
Hydromorphone—Chills—Methotrexate—psoriasis	7.57e-05	0.000246	CcSEcCtD
Hydromorphone—OPRK1—GPCR ligand binding—CCL20—psoriasis	7.52e-05	0.00434	CbGpPWpGaD
Hydromorphone—Musculoskeletal discomfort—Dexamethasone—psoriasis	7.5e-05	0.000244	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Betamethasone—psoriasis	7.5e-05	0.000244	CcSEcCtD
Hydromorphone—Pruritus—Mycophenolate mofetil—psoriasis	7.48e-05	0.000244	CcSEcCtD
Hydromorphone—Arthralgia—Prednisone—psoriasis	7.48e-05	0.000243	CcSEcCtD
Hydromorphone—Myalgia—Prednisone—psoriasis	7.48e-05	0.000243	CcSEcCtD
Hydromorphone—Feeling abnormal—Triamcinolone—psoriasis	7.48e-05	0.000243	CcSEcCtD
Hydromorphone—Anxiety—Prednisone—psoriasis	7.45e-05	0.000243	CcSEcCtD
Hydromorphone—Insomnia—Dexamethasone—psoriasis	7.45e-05	0.000242	CcSEcCtD
Hydromorphone—Insomnia—Betamethasone—psoriasis	7.45e-05	0.000242	CcSEcCtD
Hydromorphone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	7.44e-05	0.00429	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—HCAR2—psoriasis	7.43e-05	0.00429	CbGpPWpGaD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	7.43e-05	0.000242	CcSEcCtD
Hydromorphone—Diarrhoea—Cyclosporine—psoriasis	7.42e-05	0.000241	CcSEcCtD
Hydromorphone—Paraesthesia—Betamethasone—psoriasis	7.39e-05	0.000241	CcSEcCtD
Hydromorphone—Paraesthesia—Dexamethasone—psoriasis	7.39e-05	0.000241	CcSEcCtD
Hydromorphone—Discomfort—Prednisone—psoriasis	7.39e-05	0.000241	CcSEcCtD
Hydromorphone—Mental disorder—Methotrexate—psoriasis	7.39e-05	0.000241	CcSEcCtD
Hydromorphone—Erythema—Methotrexate—psoriasis	7.34e-05	0.000239	CcSEcCtD
Hydromorphone—Malnutrition—Methotrexate—psoriasis	7.34e-05	0.000239	CcSEcCtD
Hydromorphone—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	7.33e-05	0.00423	CbGpPWpGaD
Hydromorphone—Hypersensitivity—Prednisolone—psoriasis	7.27e-05	0.000237	CcSEcCtD
Hydromorphone—Dyspepsia—Dexamethasone—psoriasis	7.25e-05	0.000236	CcSEcCtD
Hydromorphone—Dyspepsia—Betamethasone—psoriasis	7.25e-05	0.000236	CcSEcCtD
Hydromorphone—Diarrhoea—Mycophenolate mofetil—psoriasis	7.24e-05	0.000236	CcSEcCtD
Hydromorphone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.24e-05	0.00418	CbGpPWpGaD
Hydromorphone—Urticaria—Triamcinolone—psoriasis	7.21e-05	0.000235	CcSEcCtD
Hydromorphone—Dysgeusia—Methotrexate—psoriasis	7.19e-05	0.000234	CcSEcCtD
Hydromorphone—Body temperature increased—Triamcinolone—psoriasis	7.17e-05	0.000233	CcSEcCtD
Hydromorphone—Dizziness—Cyclosporine—psoriasis	7.17e-05	0.000233	CcSEcCtD
Hydromorphone—Anaphylactic shock—Prednisone—psoriasis	7.17e-05	0.000233	CcSEcCtD
Hydromorphone—Decreased appetite—Dexamethasone—psoriasis	7.16e-05	0.000233	CcSEcCtD
Hydromorphone—Decreased appetite—Betamethasone—psoriasis	7.16e-05	0.000233	CcSEcCtD
Hydromorphone—Infection—Prednisone—psoriasis	7.12e-05	0.000232	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Betamethasone—psoriasis	7.11e-05	0.000231	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Dexamethasone—psoriasis	7.11e-05	0.000231	CcSEcCtD
Hydromorphone—Back pain—Methotrexate—psoriasis	7.1e-05	0.000231	CcSEcCtD
Hydromorphone—Hypersensitivity—Hydrocortisone—psoriasis	7.1e-05	0.000231	CcSEcCtD
Hydromorphone—Fatigue—Dexamethasone—psoriasis	7.1e-05	0.000231	CcSEcCtD
Hydromorphone—Fatigue—Betamethasone—psoriasis	7.1e-05	0.000231	CcSEcCtD
Hydromorphone—Shock—Prednisone—psoriasis	7.05e-05	0.00023	CcSEcCtD
Hydromorphone—Pain—Dexamethasone—psoriasis	7.04e-05	0.000229	CcSEcCtD
Hydromorphone—Pain—Betamethasone—psoriasis	7.04e-05	0.000229	CcSEcCtD
Hydromorphone—Nervous system disorder—Prednisone—psoriasis	7.03e-05	0.000229	CcSEcCtD
Hydromorphone—Tachycardia—Prednisone—psoriasis	7e-05	0.000228	CcSEcCtD
Hydromorphone—Dizziness—Mycophenolate mofetil—psoriasis	6.99e-05	0.000228	CcSEcCtD
Hydromorphone—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	6.98e-05	0.00403	CbGpPWpGaD
Hydromorphone—Skin disorder—Prednisone—psoriasis	6.96e-05	0.000227	CcSEcCtD
Hydromorphone—Hyperhidrosis—Prednisone—psoriasis	6.93e-05	0.000226	CcSEcCtD
Hydromorphone—Vision blurred—Methotrexate—psoriasis	6.92e-05	0.000225	CcSEcCtD
Hydromorphone—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	6.92e-05	0.00399	CbGpPWpGaD
Hydromorphone—Asthenia—Hydrocortisone—psoriasis	6.91e-05	0.000225	CcSEcCtD
Hydromorphone—Vomiting—Cyclosporine—psoriasis	6.89e-05	0.000224	CcSEcCtD
Hydromorphone—Rash—Cyclosporine—psoriasis	6.84e-05	0.000223	CcSEcCtD
Hydromorphone—Anorexia—Prednisone—psoriasis	6.83e-05	0.000222	CcSEcCtD
Hydromorphone—Dermatitis—Cyclosporine—psoriasis	6.83e-05	0.000222	CcSEcCtD
Hydromorphone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	6.83e-05	0.00394	CbGpPWpGaD
Hydromorphone—Pruritus—Hydrocortisone—psoriasis	6.82e-05	0.000222	CcSEcCtD
Hydromorphone—Ill-defined disorder—Methotrexate—psoriasis	6.81e-05	0.000222	CcSEcCtD
Hydromorphone—Headache—Cyclosporine—psoriasis	6.79e-05	0.000221	CcSEcCtD
Hydromorphone—Feeling abnormal—Dexamethasone—psoriasis	6.78e-05	0.000221	CcSEcCtD
Hydromorphone—Feeling abnormal—Betamethasone—psoriasis	6.78e-05	0.000221	CcSEcCtD
Hydromorphone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.78e-05	0.00391	CbGpPWpGaD
Hydromorphone—Gastrointestinal pain—Dexamethasone—psoriasis	6.73e-05	0.000219	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Betamethasone—psoriasis	6.73e-05	0.000219	CcSEcCtD
Hydromorphone—Vomiting—Mycophenolate mofetil—psoriasis	6.73e-05	0.000219	CcSEcCtD
Hydromorphone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.69e-05	0.00386	CbGpPWpGaD
Hydromorphone—Hypersensitivity—Triamcinolone—psoriasis	6.69e-05	0.000218	CcSEcCtD
Hydromorphone—Rash—Mycophenolate mofetil—psoriasis	6.67e-05	0.000217	CcSEcCtD
Hydromorphone—Dermatitis—Mycophenolate mofetil—psoriasis	6.66e-05	0.000217	CcSEcCtD
Hydromorphone—Headache—Mycophenolate mofetil—psoriasis	6.63e-05	0.000216	CcSEcCtD
Hydromorphone—Malaise—Methotrexate—psoriasis	6.62e-05	0.000216	CcSEcCtD
Hydromorphone—Vertigo—Methotrexate—psoriasis	6.6e-05	0.000215	CcSEcCtD
Hydromorphone—Diarrhoea—Hydrocortisone—psoriasis	6.59e-05	0.000215	CcSEcCtD
Hydromorphone—Leukopenia—Methotrexate—psoriasis	6.57e-05	0.000214	CcSEcCtD
Hydromorphone—Urticaria—Betamethasone—psoriasis	6.54e-05	0.000213	CcSEcCtD
Hydromorphone—Urticaria—Dexamethasone—psoriasis	6.54e-05	0.000213	CcSEcCtD
Hydromorphone—Musculoskeletal discomfort—Prednisone—psoriasis	6.53e-05	0.000213	CcSEcCtD
Hydromorphone—Dizziness—Prednisolone—psoriasis	6.52e-05	0.000212	CcSEcCtD
Hydromorphone—Asthenia—Triamcinolone—psoriasis	6.51e-05	0.000212	CcSEcCtD
Hydromorphone—Body temperature increased—Betamethasone—psoriasis	6.51e-05	0.000212	CcSEcCtD
Hydromorphone—Body temperature increased—Dexamethasone—psoriasis	6.51e-05	0.000212	CcSEcCtD
Hydromorphone—Abdominal pain—Betamethasone—psoriasis	6.51e-05	0.000212	CcSEcCtD
Hydromorphone—Abdominal pain—Dexamethasone—psoriasis	6.51e-05	0.000212	CcSEcCtD
Hydromorphone—Insomnia—Prednisone—psoriasis	6.48e-05	0.000211	CcSEcCtD
Hydromorphone—Nausea—Cyclosporine—psoriasis	6.44e-05	0.00021	CcSEcCtD
Hydromorphone—Paraesthesia—Prednisone—psoriasis	6.44e-05	0.00021	CcSEcCtD
Hydromorphone—Pruritus—Triamcinolone—psoriasis	6.42e-05	0.000209	CcSEcCtD
Hydromorphone—Cough—Methotrexate—psoriasis	6.41e-05	0.000209	CcSEcCtD
Hydromorphone—Dizziness—Hydrocortisone—psoriasis	6.37e-05	0.000207	CcSEcCtD
Hydromorphone—Convulsion—Methotrexate—psoriasis	6.36e-05	0.000207	CcSEcCtD
Hydromorphone—OPRM1—GPCR ligand binding—CCL20—psoriasis	6.36e-05	0.00367	CbGpPWpGaD
Hydromorphone—OPRM1—TCR Signaling Pathway—CD4—psoriasis	6.35e-05	0.00366	CbGpPWpGaD
Hydromorphone—Dyspepsia—Prednisone—psoriasis	6.31e-05	0.000205	CcSEcCtD
Hydromorphone—Nausea—Mycophenolate mofetil—psoriasis	6.28e-05	0.000205	CcSEcCtD
Hydromorphone—OPRM1—Signaling by GPCR—HCAR2—psoriasis	6.28e-05	0.00362	CbGpPWpGaD
Hydromorphone—Arthralgia—Methotrexate—psoriasis	6.25e-05	0.000203	CcSEcCtD
Hydromorphone—Myalgia—Methotrexate—psoriasis	6.25e-05	0.000203	CcSEcCtD
Hydromorphone—Chest pain—Methotrexate—psoriasis	6.25e-05	0.000203	CcSEcCtD
Hydromorphone—Decreased appetite—Prednisone—psoriasis	6.23e-05	0.000203	CcSEcCtD
Hydromorphone—Rash—Prednisolone—psoriasis	6.22e-05	0.000203	CcSEcCtD
Hydromorphone—Dermatitis—Prednisolone—psoriasis	6.22e-05	0.000202	CcSEcCtD
Hydromorphone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.21e-05	0.000202	CcSEcCtD
Hydromorphone—Fatigue—Prednisone—psoriasis	6.18e-05	0.000201	CcSEcCtD
Hydromorphone—Headache—Prednisolone—psoriasis	6.18e-05	0.000201	CcSEcCtD
Hydromorphone—Discomfort—Methotrexate—psoriasis	6.18e-05	0.000201	CcSEcCtD
Hydromorphone—Constipation—Prednisone—psoriasis	6.13e-05	0.0002	CcSEcCtD
Hydromorphone—Vomiting—Hydrocortisone—psoriasis	6.13e-05	0.000199	CcSEcCtD
Hydromorphone—Rash—Hydrocortisone—psoriasis	6.08e-05	0.000198	CcSEcCtD
Hydromorphone—Dermatitis—Hydrocortisone—psoriasis	6.07e-05	0.000198	CcSEcCtD
Hydromorphone—Confusional state—Methotrexate—psoriasis	6.04e-05	0.000197	CcSEcCtD
Hydromorphone—Headache—Hydrocortisone—psoriasis	6.04e-05	0.000197	CcSEcCtD
Hydromorphone—Dizziness—Triamcinolone—psoriasis	6e-05	0.000195	CcSEcCtD
Hydromorphone—Anaphylactic shock—Methotrexate—psoriasis	5.99e-05	0.000195	CcSEcCtD
Hydromorphone—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	5.98e-05	0.00345	CbGpPWpGaD
Hydromorphone—Infection—Methotrexate—psoriasis	5.95e-05	0.000194	CcSEcCtD
Hydromorphone—Feeling abnormal—Prednisone—psoriasis	5.91e-05	0.000192	CcSEcCtD
Hydromorphone—Asthenia—Betamethasone—psoriasis	5.91e-05	0.000192	CcSEcCtD
Hydromorphone—Asthenia—Dexamethasone—psoriasis	5.91e-05	0.000192	CcSEcCtD
Hydromorphone—Nervous system disorder—Methotrexate—psoriasis	5.88e-05	0.000191	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Prednisone—psoriasis	5.86e-05	0.000191	CcSEcCtD
Hydromorphone—Nausea—Prednisolone—psoriasis	5.86e-05	0.000191	CcSEcCtD
Hydromorphone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.85e-05	0.00338	CbGpPWpGaD
Hydromorphone—Pruritus—Dexamethasone—psoriasis	5.82e-05	0.00019	CcSEcCtD
Hydromorphone—Pruritus—Betamethasone—psoriasis	5.82e-05	0.00019	CcSEcCtD
Hydromorphone—Skin disorder—Methotrexate—psoriasis	5.82e-05	0.000189	CcSEcCtD
Hydromorphone—Hyperhidrosis—Methotrexate—psoriasis	5.79e-05	0.000189	CcSEcCtD
Hydromorphone—Vomiting—Triamcinolone—psoriasis	5.77e-05	0.000188	CcSEcCtD
Hydromorphone—Nausea—Hydrocortisone—psoriasis	5.72e-05	0.000186	CcSEcCtD
Hydromorphone—Rash—Triamcinolone—psoriasis	5.72e-05	0.000186	CcSEcCtD
Hydromorphone—Dermatitis—Triamcinolone—psoriasis	5.72e-05	0.000186	CcSEcCtD
Hydromorphone—Anorexia—Methotrexate—psoriasis	5.71e-05	0.000186	CcSEcCtD
Hydromorphone—Urticaria—Prednisone—psoriasis	5.7e-05	0.000185	CcSEcCtD
Hydromorphone—Headache—Triamcinolone—psoriasis	5.68e-05	0.000185	CcSEcCtD
Hydromorphone—OPRM1—TCR Signaling Pathway—JUN—psoriasis	5.68e-05	0.00328	CbGpPWpGaD
Hydromorphone—Abdominal pain—Prednisone—psoriasis	5.67e-05	0.000184	CcSEcCtD
Hydromorphone—Body temperature increased—Prednisone—psoriasis	5.67e-05	0.000184	CcSEcCtD
Hydromorphone—Diarrhoea—Betamethasone—psoriasis	5.63e-05	0.000183	CcSEcCtD
Hydromorphone—Diarrhoea—Dexamethasone—psoriasis	5.63e-05	0.000183	CcSEcCtD
Hydromorphone—Hypotension—Methotrexate—psoriasis	5.6e-05	0.000182	CcSEcCtD
Hydromorphone—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	5.58e-05	0.00322	CbGpPWpGaD
Hydromorphone—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	5.47e-05	0.00316	CbGpPWpGaD
Hydromorphone—Musculoskeletal discomfort—Methotrexate—psoriasis	5.46e-05	0.000178	CcSEcCtD
Hydromorphone—Dizziness—Betamethasone—psoriasis	5.44e-05	0.000177	CcSEcCtD
Hydromorphone—Dizziness—Dexamethasone—psoriasis	5.44e-05	0.000177	CcSEcCtD
Hydromorphone—Insomnia—Methotrexate—psoriasis	5.42e-05	0.000176	CcSEcCtD
Hydromorphone—Nausea—Triamcinolone—psoriasis	5.39e-05	0.000175	CcSEcCtD
Hydromorphone—Paraesthesia—Methotrexate—psoriasis	5.38e-05	0.000175	CcSEcCtD
Hydromorphone—Dyspnoea—Methotrexate—psoriasis	5.34e-05	0.000174	CcSEcCtD
Hydromorphone—Somnolence—Methotrexate—psoriasis	5.33e-05	0.000173	CcSEcCtD
Hydromorphone—Hypersensitivity—Prednisone—psoriasis	5.28e-05	0.000172	CcSEcCtD
Hydromorphone—Dyspepsia—Methotrexate—psoriasis	5.27e-05	0.000172	CcSEcCtD
Hydromorphone—Vomiting—Dexamethasone—psoriasis	5.23e-05	0.00017	CcSEcCtD
Hydromorphone—Vomiting—Betamethasone—psoriasis	5.23e-05	0.00017	CcSEcCtD
Hydromorphone—Decreased appetite—Methotrexate—psoriasis	5.21e-05	0.00017	CcSEcCtD
Hydromorphone—Rash—Betamethasone—psoriasis	5.19e-05	0.000169	CcSEcCtD
Hydromorphone—Rash—Dexamethasone—psoriasis	5.19e-05	0.000169	CcSEcCtD
Hydromorphone—Dermatitis—Betamethasone—psoriasis	5.19e-05	0.000169	CcSEcCtD
Hydromorphone—Dermatitis—Dexamethasone—psoriasis	5.19e-05	0.000169	CcSEcCtD
Hydromorphone—Gastrointestinal disorder—Methotrexate—psoriasis	5.17e-05	0.000168	CcSEcCtD
Hydromorphone—Fatigue—Methotrexate—psoriasis	5.17e-05	0.000168	CcSEcCtD
Hydromorphone—Headache—Betamethasone—psoriasis	5.16e-05	0.000168	CcSEcCtD
Hydromorphone—Headache—Dexamethasone—psoriasis	5.16e-05	0.000168	CcSEcCtD
Hydromorphone—Asthenia—Prednisone—psoriasis	5.14e-05	0.000167	CcSEcCtD
Hydromorphone—Pain—Methotrexate—psoriasis	5.12e-05	0.000167	CcSEcCtD
Hydromorphone—Pruritus—Prednisone—psoriasis	5.07e-05	0.000165	CcSEcCtD
Hydromorphone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.04e-05	0.00291	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—HCAR2—psoriasis	5.01e-05	0.00289	CbGpPWpGaD
Hydromorphone—Feeling abnormal—Methotrexate—psoriasis	4.94e-05	0.000161	CcSEcCtD
Hydromorphone—Diarrhoea—Prednisone—psoriasis	4.91e-05	0.00016	CcSEcCtD
Hydromorphone—Gastrointestinal pain—Methotrexate—psoriasis	4.9e-05	0.000159	CcSEcCtD
Hydromorphone—Nausea—Betamethasone—psoriasis	4.89e-05	0.000159	CcSEcCtD
Hydromorphone—Nausea—Dexamethasone—psoriasis	4.89e-05	0.000159	CcSEcCtD
Hydromorphone—OPRD1—GPCR downstream signaling—CCL20—psoriasis	4.85e-05	0.0028	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—NDUFA5—psoriasis	4.83e-05	0.00279	CbGpPWpGaD
Hydromorphone—Urticaria—Methotrexate—psoriasis	4.76e-05	0.000155	CcSEcCtD
Hydromorphone—Dizziness—Prednisone—psoriasis	4.74e-05	0.000154	CcSEcCtD
Hydromorphone—Abdominal pain—Methotrexate—psoriasis	4.74e-05	0.000154	CcSEcCtD
Hydromorphone—Body temperature increased—Methotrexate—psoriasis	4.74e-05	0.000154	CcSEcCtD
Hydromorphone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	4.7e-05	0.00271	CbGpPWpGaD
Hydromorphone—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	4.64e-05	0.00268	CbGpPWpGaD
Hydromorphone—Vomiting—Prednisone—psoriasis	4.56e-05	0.000148	CcSEcCtD
Hydromorphone—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.54e-05	0.00262	CbGpPWpGaD
Hydromorphone—Rash—Prednisone—psoriasis	4.52e-05	0.000147	CcSEcCtD
Hydromorphone—Dermatitis—Prednisone—psoriasis	4.52e-05	0.000147	CcSEcCtD
Hydromorphone—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.5e-05	0.0026	CbGpPWpGaD
Hydromorphone—Headache—Prednisone—psoriasis	4.49e-05	0.000146	CcSEcCtD
Hydromorphone—Hypersensitivity—Methotrexate—psoriasis	4.41e-05	0.000144	CcSEcCtD
Hydromorphone—OPRD1—Signaling by GPCR—CCL20—psoriasis	4.4e-05	0.00254	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—HCAR2—psoriasis	4.39e-05	0.00253	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—TAGAP—psoriasis	4.34e-05	0.00251	CbGpPWpGaD
Hydromorphone—Asthenia—Methotrexate—psoriasis	4.3e-05	0.00014	CcSEcCtD
Hydromorphone—Nausea—Prednisone—psoriasis	4.26e-05	0.000139	CcSEcCtD
Hydromorphone—OPRK1—GPCR downstream signaling—CCL20—psoriasis	4.25e-05	0.00245	CbGpPWpGaD
Hydromorphone—Pruritus—Methotrexate—psoriasis	4.24e-05	0.000138	CcSEcCtD
Hydromorphone—UGT1A9—Metabolism—CYP2S1—psoriasis	4.1e-05	0.00237	CbGpPWpGaD
Hydromorphone—Diarrhoea—Methotrexate—psoriasis	4.1e-05	0.000133	CcSEcCtD
Hydromorphone—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	3.98e-05	0.00229	CbGpPWpGaD
Hydromorphone—Dizziness—Methotrexate—psoriasis	3.96e-05	0.000129	CcSEcCtD
Hydromorphone—PTGS1—Metabolism—NDUFA5—psoriasis	3.93e-05	0.00227	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—CCL20—psoriasis	3.86e-05	0.00223	CbGpPWpGaD
Hydromorphone—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	3.83e-05	0.00221	CbGpPWpGaD
Hydromorphone—Vomiting—Methotrexate—psoriasis	3.81e-05	0.000124	CcSEcCtD
Hydromorphone—OPRK1—Signaling Pathways—TAGAP—psoriasis	3.81e-05	0.0022	CbGpPWpGaD
Hydromorphone—Rash—Methotrexate—psoriasis	3.78e-05	0.000123	CcSEcCtD
Hydromorphone—Dermatitis—Methotrexate—psoriasis	3.77e-05	0.000123	CcSEcCtD
Hydromorphone—Headache—Methotrexate—psoriasis	3.75e-05	0.000122	CcSEcCtD
Hydromorphone—OPRM1—Signaling Pathways—HCAR2—psoriasis	3.71e-05	0.00214	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.67e-05	0.00212	CbGpPWpGaD
Hydromorphone—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.61e-05	0.00208	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—CCL20—psoriasis	3.59e-05	0.00207	CbGpPWpGaD
Hydromorphone—Nausea—Methotrexate—psoriasis	3.56e-05	0.000116	CcSEcCtD
Hydromorphone—OPRM1—TCR Signaling Pathway—IL6—psoriasis	3.43e-05	0.00198	CbGpPWpGaD
Hydromorphone—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	3.36e-05	0.00194	CbGpPWpGaD
Hydromorphone—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	3.36e-05	0.00194	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—CYP2S1—psoriasis	3.35e-05	0.00193	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—CCL20—psoriasis	3.26e-05	0.00188	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—TAGAP—psoriasis	3.22e-05	0.00186	CbGpPWpGaD
Hydromorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.04e-05	0.00176	CbGpPWpGaD
Hydromorphone—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.91e-05	0.00168	CbGpPWpGaD
Hydromorphone—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	2.84e-05	0.00164	CbGpPWpGaD
Hydromorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.67e-05	0.00154	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CCL20—psoriasis	2.6e-05	0.0015	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR ligand binding—CXCL8—psoriasis	2.32e-05	0.00134	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CCL20—psoriasis	2.28e-05	0.00132	CbGpPWpGaD
Hydromorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.25e-05	0.0013	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.15e-05	0.00124	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—NDUFA5—psoriasis	2.09e-05	0.0012	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—NDUFA5—psoriasis	2.07e-05	0.00119	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR ligand binding—CXCL8—psoriasis	2.03e-05	0.00117	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—CARM1—psoriasis	2e-05	0.00116	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.93e-05	0.00111	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CCL20—psoriasis	1.93e-05	0.00111	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.87e-05	0.00108	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CYP2S1—psoriasis	1.77e-05	0.00102	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CYP2S1—psoriasis	1.76e-05	0.00101	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.75e-05	0.00101	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR ligand binding—CXCL8—psoriasis	1.72e-05	0.000991	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—CARM1—psoriasis	1.63e-05	0.000943	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.53e-05	0.000881	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—SOCS1—psoriasis	1.43e-05	0.000826	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—TYK2—psoriasis	1.37e-05	0.000788	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.36e-05	0.000787	CbGpPWpGaD
Hydromorphone—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	1.31e-05	0.000755	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—SOCS1—psoriasis	1.26e-05	0.000725	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—CAT—psoriasis	1.23e-05	0.000711	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—TYK2—psoriasis	1.2e-05	0.000691	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—CXCL8—psoriasis	1.19e-05	0.000686	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CYP2S1—psoriasis	1.16e-05	0.000669	CbGpPWpGaD
Hydromorphone—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	1.15e-05	0.000662	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—SOCS1—psoriasis	1.06e-05	0.000612	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—APOE—psoriasis	1.06e-05	0.00061	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—LEP—psoriasis	1.06e-05	0.00061	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—CXCL8—psoriasis	1.04e-05	0.000602	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.01e-05	0.000584	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—CAT—psoriasis	1.01e-05	0.00058	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—NFKBIA—psoriasis	9.85e-06	0.000568	CbGpPWpGaD
Hydromorphone—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	9.7e-06	0.00056	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—APOE—psoriasis	9.58e-06	0.000553	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—LEP—psoriasis	9.27e-06	0.000535	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—APOE—psoriasis	9.27e-06	0.000535	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.22e-06	0.000532	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—CXCL8—psoriasis	8.81e-06	0.000508	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CARM1—psoriasis	8.66e-06	0.0005	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—NFKBIA—psoriasis	8.64e-06	0.000498	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CARM1—psoriasis	8.59e-06	0.000496	CbGpPWpGaD
Hydromorphone—UGT1A9—Metabolism—PPARG—psoriasis	8.34e-06	0.000481	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—TYK2—psoriasis	8.07e-06	0.000465	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.03e-06	0.000463	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—APOE—psoriasis	7.83e-06	0.000452	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—LEP—psoriasis	7.83e-06	0.000452	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—APOE—psoriasis	7.81e-06	0.000451	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—NFKBIA—psoriasis	7.3e-06	0.000421	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—TYK2—psoriasis	7.07e-06	0.000408	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—CXCL8—psoriasis	7.02e-06	0.000405	CbGpPWpGaD
Hydromorphone—PTGS1—Metabolism—PPARG—psoriasis	6.8e-06	0.000392	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling by GPCR—IL6—psoriasis	6.68e-06	0.000385	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—JUN—psoriasis	6.53e-06	0.000377	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—NFKB1—psoriasis	6.29e-06	0.000363	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—CXCL8—psoriasis	6.16e-06	0.000355	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—TYK2—psoriasis	5.98e-06	0.000345	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling by GPCR—IL6—psoriasis	5.86e-06	0.000338	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—JUN—psoriasis	5.73e-06	0.00033	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—VEGFA—psoriasis	5.7e-06	0.000329	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CARM1—psoriasis	5.67e-06	0.000327	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—STAT3—psoriasis	5.65e-06	0.000326	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—NFKB1—psoriasis	5.51e-06	0.000318	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—CAT—psoriasis	5.33e-06	0.000308	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—CAT—psoriasis	5.28e-06	0.000305	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—CXCL8—psoriasis	5.21e-06	0.0003	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—VEGFA—psoriasis	5e-06	0.000289	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—STAT3—psoriasis	4.95e-06	0.000286	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling by GPCR—IL6—psoriasis	4.95e-06	0.000286	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—JUN—psoriasis	4.84e-06	0.000279	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—NFKB1—psoriasis	4.66e-06	0.000269	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—TP53—psoriasis	4.31e-06	0.000249	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—VEGFA—psoriasis	4.23e-06	0.000244	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—STAT3—psoriasis	4.19e-06	0.000242	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—APOE—psoriasis	4.14e-06	0.000239	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—APOE—psoriasis	4.11e-06	0.000237	CbGpPWpGaD
Hydromorphone—OPRD1—Signaling Pathways—IL6—psoriasis	3.95e-06	0.000228	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—TP53—psoriasis	3.78e-06	0.000218	CbGpPWpGaD
Hydromorphone—CYP2D6—Metabolism—PPARG—psoriasis	3.61e-06	0.000208	CbGpPWpGaD
Hydromorphone—CYP2C9—Metabolism—PPARG—psoriasis	3.58e-06	0.000206	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—CAT—psoriasis	3.48e-06	0.000201	CbGpPWpGaD
Hydromorphone—OPRK1—Signaling Pathways—IL6—psoriasis	3.46e-06	0.0002	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—TP53—psoriasis	3.19e-06	0.000184	CbGpPWpGaD
Hydromorphone—OPRM1—Signaling Pathways—IL6—psoriasis	2.92e-06	0.000169	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—APOE—psoriasis	2.71e-06	0.000156	CbGpPWpGaD
Hydromorphone—CYP3A4—Metabolism—PPARG—psoriasis	2.36e-06	0.000136	CbGpPWpGaD
